Loading…
Loading…
TNFA (TNF Pharmaceuticals, Inc.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
TNF Pharmaceuticals, Inc. (NASDAQ: TNFA - Get Free Report) shares shot up 0.8% during trading on Thursday. The stock traded as high as $4.15 and last traded at $3.83. 459,933 shares traded hands during mid-day trading, a decline of 99% from the average session volume of 32,220,806 shares. The stock had previously closed at $3.80.
TNF Pharmaceuticals (NASDAQ: TNFA - Get Free Report) and Altimmune (NASDAQ: ALT - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability. Risk and Volatility TNF Pharmaceuticals has a beta
NEW YORK--(BUSINESS WIRE)---- $QCLS--Q/C Technologies, Inc. (Nasdaq: QCLS), formerly TNF Pharmaceuticals, Inc. (Nasdaq: TNFA), (“Q/C” or “the Company”), today announced that its common stock will begin trading under the new ticker symbol “QCLS” beginning today at the market open. The Company's new name Q/C Technologies represents its recent strategic pivot into quantum-class computing with exclusive global rights to LightSolver's light-speed laser processing unit (LPU), the world's first light and laser-.
NEW YORK--(BUSINESS WIRE)---- $TNFA--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“Q/C” or the “Company”) today announced that it has changed its corporate name to Q/C Technologies, Inc. and will begin trading under the new ticker symbol “QCLS” on the Nasdaq Capital Market, effective as of the market open on Thursday, September 25, 2025. Until then, the Company's common stock will continue to trade under its current ticker symbol “TNFA.” The new name Q/C Technologies represents the Company's recent strategi.
NEW YORK--(BUSINESS WIRE)---- $TNFA--TNF Pharmaceuticals Inc. (Nasdaq: TNFA), (“TNF” or the “Company”) today announced that it received written notice from the Nasdaq Stock Market on September 16, 2025, confirming that the Company has regained compliance with Nasdaq's $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550 (a)(2). To regain compliance with the Listing Rule, the Company's shares maintained the minimum bid price of $1.00 for 10 consecutive business days. "We are pleased to have.
NEW YORK--(BUSINESS WIRE)---- $TNFA--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”) today announced the closing of a $7.0 million private placement financing of convertible preferred stock with the Company's largest strategic stockholder and other existing stockholders. The private placement involved the sale of 7,000 shares of preferred stock, with a stated value of $1,000 per share, convertible into 1,400,000 million shares of the Company's common stock at an initial conversion price.
NEW YORK--(BUSINESS WIRE)---- $TNFA--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that is has significantly improved its financial position over the past 5 months through a material reduction in liabilities, while maintaining total assets of over $17 million as of June 30, 2025. “The recent significant improvement in our financial position gi.
NEW YORK--(BUSINESS WIRE)---- $TNFA--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that it has formed a philanthropic collaboration with the DADA2 Foundation, a nonprofit organization seeking innovative ways to accelerate research into the rare inflammatory disease DADA2 (Deficiency of Adenosine Deaminase 2). Together, the parties are expected.
No recent filings indexed.